bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53
Authors: Karan Goutam , Wang Huaiyu , Chakrabarti Amit , Karan Sukanya , Liu Zhigang , Xia Zhiqiang , Gundluru Mahesh , Moreton Stephen , Saunthararajah Yogen , Jackson Mark W. , Agarwal Mukesh K. , Wald David N.
Published: April 2023

CTX1 specifically interacts with HdmX.
Supplementary Figure 1 from Secretory TRAIL-Armed Natural Killer Cell–Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft
Authors: Song Xinxin , Hong Se-Hoon , Kwon William T. , Bailey Lisa M. , Basse Per , Bartlett David L. , Kwon Yong Tae , Lee Yong J.
Published: April 2023

Apoptotic activity of secretory TRAIL-armed NK cells in a contacting culture system
Supplementary Table S5 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Statistical analysis comparing efficacy between study arms of AZD8835 in vivo combination studies.
Supplementary Table 1. from Src as a Therapeutic Target in Biliary Tract Cancer
Authors: Nam Ah-Rong , Kim Ji-Won , Park Ji Eun , Bang Ju-Hee , Jin Mei Hua , Lee Kyung-Hun , Kim Tae-Yong , Han Sae-Won , Im Seock-Ah , Kim Tae-You , Oh Do-Youn , Bang Yung-Jue
Published: April 2023

Supplementary Table 1. The IC50 values of bosutinib, gemcitabine, and cisplatin in biliary tract cancer cell lines.
Supplementary Tables and Figures Legends from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Authors: Andreev Julian , Thambi Nithya , Perez Bay Andres E. , Delfino Frank , Martin Joel , Kelly Marcus P. , Kirshner Jessica R. , Rafique Ashique , Kunz Arthur , Nittoli Thomas , MacDonald Douglas , Daly Christopher , Olson William , Thurston Gavin
Published: April 2023

Supplementary Tables and Figures Legends
Supplementary Figure S5 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Authors: Andreev Julian , Thambi Nithya , Perez Bay Andres E. , Delfino Frank , Martin Joel , Kelly Marcus P. , Kirshner Jessica R. , Rafique Ashique , Kunz Arthur , Nittoli Thomas , MacDonald Douglas , Daly Christopher , Olson William , Thurston Gavin
Published: April 2023

In T47D/HER2 cells, HER2xPRLR bsAb1 augments HER2 ADCinduced cell cycle arrest in G2M phase.
Supplementary Figure S3 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Authors: Andreev Julian , Thambi Nithya , Perez Bay Andres E. , Delfino Frank , Martin Joel , Kelly Marcus P. , Kirshner Jessica R. , Rafique Ashique , Kunz Arthur , Nittoli Thomas , MacDonald Douglas , Daly Christopher , Olson William , Thurston Gavin
Published: April 2023

PRLR degradation was not significantly affected by PRLR antibody or Prolactin (PRL).
Supp Materials legends from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

Legends for Supplementary Figures and Tables
Supplementary table 5. from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Functions associated with LM04, DEPDC and FOXM1 genes.
Figure S6 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Authors: Garcia Tamara B. , Snedeker Jonathan C. , Baturin Dmitry , Gardner Lori , Fosmire Susan P. , Zhou Chengjing , Jordan Craig T. , Venkataraman Sujatha , Vibhakar Rajeev , Porter Christopher C.
Published: April 2023

Combined AZD1775 and olaparib treatment reduces cell viability and enhances apoptosis in a murine AML cell line. A. A murine MLL-ENL, FLT3-ITD+ AML cell line was treated in vitro with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 (200 nM) for 72 hr. Viable cell counts are normalized to cells receiving no treatment (NT). Results are shown as mean {plus minus} SEM from three independent experiments. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 0.0001. B. A murine AML cell line was treated in vitro with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 (200 nM) for 72 hr then stained with Annexin V-PE. Results are displayed as mean {plus minus} SEM of three independent experiments. **, P < 0.01. ***, P < 0.001. ****, P < 0.0001.
Legends Supplemental Figures from Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
Authors: de Lint Klaas , Poell Jos B. , Soueidan Hayssam , Jastrzebski Katarzyna , Vidal Rodriguez Jordi , Lieftink Cor , Wessels Lodewyk F.A. , Beijersbergen Roderick L.
Published: April 2023

Legends Supplemental Figures 1-9 and Tables 1-5
Figure S2 from Combined PPARγ Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors
Authors: Leung Dilys T.H. , Nguyen Trang , Oliver Edwina May , Matti Juliana , Alexiadis Maria , Silke John , Jobling Thomas W. , Fuller Peter J. , Chu Simon
Published: April 2023

Figure S2. Effects of PPARg activation.
Supplementary Figure S4 from Chromatin Regulators as a Guide for Cancer Treatment Choice
Authors: Gurard-Levin Zachary A. , Wilson Laurence O.W. , Pancaldi Vera , Postel-Vinay Sophie , Sousa Fabricio G. , Reyes Cecile , Marangoni Elisabetta , Gentien David , Valencia Alfonso , Pommier Yves , Cottu Paul , Almouzni Geneviève
Published: April 2023

A chromatin regulator gene panel can distinguish response in HER2+ patients treated with docetaxel
Supplementary Figure 1 from Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Authors: Ilhan-Mutlu Aysegül , Osswald Matthias , Liao Yunxiang , Gömmel Miriam , Reck Martin , Miles David , Mariani Paola , Gianni Luca , Lutiger Beatrix , Nendel Viktor , Srock Stefanie , Perez-Moreno Pablo , Thorsen Frits , von Baumgarten Louisa , Preusser Matthias , Wick Wolfgang , Winkler Frank
Published: April 2023

Time from randomization to new brain lesions in AVAiL Trial
Supp Figure 3 from Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
Authors: Bisi John E. , Sorrentino Jessica A. , Roberts Patrick J. , Tavares Francis X. , Strum Jay C.
Published: April 2023

Combination therapy of G1T28 and topotecan does not cause a DDI effect.
Supplementary Figures 1-3 from Induction of MNK Kinase–dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors
Authors: Pham Thao N.D. , Kumar Krishan , DeCant Brian T. , Shang Meng , Munshi Samad Z. , Matsangou Maria , Ebine Kazumi , Munshi Hidayatullah G.
Published: April 2023

Fig. S1 - eIF4E expression and survival data for papillary thyroid. Fig. S2 - Effect of BET inhibitors on genes regulating cytoskeleton Fig. S3 - combination of MNK inhibitors and OTX015 or ARV-825
Supplementary Figure 4 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

Growth of cells from different solid tumors in the 3D-TGA.
Supplementary Data. from HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
Authors: Press Michael F. , Ellis Catherine E. , Gagnon Robert C. , Grob Tobias J. , Buyse Marc , Villalobos Ivonne , Liang Zhiyong , Wu Shafei , Bang Yung-Jue , Qin Shu-Kui , Chung Hyun Cheol , Xu Jianming , Park Joon Oh , Jeziorski Krzysztof , Afenjar Karen , Ma Yanling , Estrada Monica C. , Robinson Douglas M. , Scherer Stefan J. , Sauter Guido , Hecht J. Randolph , Slamon Dennis J.
Published: April 2023

Supplementary Data: List of TRIO investigators, Supplementary Materials and Methods, Supplementary Results, Supplementary Discussion, Supplementary References, Supplementary Tables, and Supplementary Figures.
Figure S2 from Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo
Authors: Pan Tianhong , Martinez Mariane , Hubka Kelsea M. , Song Jian H. , Lin Song-Chang , Yu Guoyu , Lee Yu-Chen , Gallick Gary E. , Tu Shi-Ming , Harrington Daniel A. , Farach-Carson Mary C. , Lin Sue-Hwa , Satcher Robert L.
Published: April 2023

ALP and OSC gene expression in human Bo-786 RCC cells and PC3 prostate cancer cells
Supplementary Figures S1-S6 from Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Authors: Dorywalska Magdalena , Dushin Russell , Moine Ludivine , Farias Santiago E. , Zhou Dahui , Navaratnam Thayalan , Lui Victor , Hasa-Moreno Adela , Casas Meritxell Galindo , Tran Thomas-Toan , Delaria Kathy , Liu Shu-Hui , Foletti Davide , O'Donnell Christopher J. , Pons Jaume , Shelton David L. , Rajpal Arvind , Strop Pavel
Published: April 2023

S1. Enrichment of VC-PABC hydrolysis activity by mouse serum fractionation. S2. Testing of mouse serum enzymes for the VC-PABC linker hydrolysis activity. S3. Testing of mouse serum enzymes for cleavage activity towards the non-cleavable amino-PEG6-C2-MMAD linker-payload. S4. Testing mouse Ces1C for cleavage activity towards conventional cysteine-linked conjugates. S5. In vitro cytotoxicity of VC-PABC linker-payload derivatives. S6. Comparison of ADC metabolism in the plasma of different species.
Supplementary Figures 1-10 from Antagonists of IGF:Vitronectin Interactions Inhibit IGF-I–Induced Breast Cancer Cell Functions
Authors: Kashyap Abhishek S. , Shooter Gary K. , Shokoohmand Ali , McGovern Jacqui , Sivaramakrishnan Manaswini , Croll Tristan I. , Cane Gaëlle , Leavesley David I. , Söderberg Ola , Upton Zee , Hollier Brett G.
Published: April 2023

Supplementary Fig. S1: Tissue microarray VN:IGFBP-3 PLA immunoreactivity and patient information; Supplementary Fig. S2: VN peptide array amino acid sequence information; Supplementary Fig. S3: IGFBP-3 peptide array amino acid sequence information; Supplementary Fig. S4: VN and IGFBP-3 immunoreactivity of HMLER-FOXC2 primary tumour xenografts; Supplementary Fig. S5: Single channel images of in situ PLA; Supplementary Fig. S6: IGF-II-induced cell signalling in MCF-7 breast cancer cells; Supplementary Fig. S7: Breast cell migration measured using the xCELLigence assay; Supplementary Fig. S8: Optimisation of ligand binding to VN and its subsequent immunodetection; Supplementary Fig. S9: Identification of ligand binding sites on VN using information from VN peptide arrays; Supplementary Fig. S10: Binding sites on IGFBP-3 for VN using the IGFBP-3 peptide arrays
Supplementary Figures 1-6, Supplementary Methods, and Supplementary Tables 1-2 from Estrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia
Authors: Rota Sarah-Grace , Roma Alessia , Dude Iulia , Ma Christina , Stevens Robert , MacEachern Janet , Graczyk Joanna , Espiritu Shaundrei Mabriel G. , Rao Praveen N. , Minden Mark D. , Kreinin Elena , Hess David A. , Doxey Andrew C. , Spagnuolo Paul A.
Published: April 2023

Supplementary Table 1: AML patient sample characteristics sensitive to diosmetin; Supplementary Table 2: AML patient sample characteristics insensitive to diosmetin; Supplementary figure 1: The top 12 hits of the primary screen were validated and compound 73 (i.e., diosmetin; indicated by arrow) was identified as the most potent at reducing the viability of (left) TEX cells. (B) The activity of diosmetin purchased from two additional commercially available sources was confirmed; Supplementary figure 2-3: ESR1 (ERα) and ESR2 (ERβ) expression was examined in publicly available databases; Supplementary figure 4: Diosmetin had no effect on the viability of these ERα or ERβ luciferase promoter containing HeLa cells at 24h of incubation; Supplementary figure 5: Immunoblot analysis of ERβ protein in a panel of AML cell lines; Supplementary figure 6: (Left) Reactive oxygen species (ROS) were measured in TEX cells treated with 10μM diosmetin for increasing time using DCFH-DA and flow cytometry.
Supplementary Figure S2 from PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers
Authors: Packer Leisl M. , Geng Xinyan , Bonazzi Vanessa F. , Ju Robert J. , Mahon Clare E. , Cummings Margaret C. , Stephenson Sally-Anne , Pollock Pamela M.
Published: April 2023

Figure S2. Optimization of drug concentrations that induce a synergistic effect on long-term survival.
Figure S7 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Authors: Germann Ursula A. , Furey Brinley F. , Markland William , Hoover Russell R. , Aronov Alex M. , Roix Jeffrey J. , Hale Michael , Boucher Diane M. , Sorrell David A. , Martinez-Botella Gabriel , Fitzgibbon Matthew , Shapiro Paul , Wick Michael J. , Samadani Ramin , Meshaw Kathryn , Groover Anna , DeCrescenzo Gary , Namchuk Mark , Emery Caroline M. , Saha Saurabh , Welsch Dean J.
Published: April 2023

Body Weight (grams) over time (days) is shown for treatment groups in xenograft derived from a vemurafenib-relapsed patient.
Figure S6 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Authors: Germann Ursula A. , Furey Brinley F. , Markland William , Hoover Russell R. , Aronov Alex M. , Roix Jeffrey J. , Hale Michael , Boucher Diane M. , Sorrell David A. , Martinez-Botella Gabriel , Fitzgibbon Matthew , Shapiro Paul , Wick Michael J. , Samadani Ramin , Meshaw Kathryn , Groover Anna , DeCrescenzo Gary , Namchuk Mark , Emery Caroline M. , Saha Saurabh , Welsch Dean J.
Published: April 2023

In SW48 colorectal cells engineered with KRAS alleles, response to paclitaxel was unaltered.
Supplementary Figures 1-5 from Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma
Authors: Aguilera Kristina Y. , Huang Huocong , Du Wenting , Hagopian Moriah M. , Wang Zhen , Hinz Stefan , Hwang Tae Hyun , Wang Huamin , Fleming Jason B. , Castrillon Diego H. , Ren Xiaomei , Ding Ke , Brekken Rolf A.
Published: April 2023

Supplementary Figure 1: 7rh reduces collagen-mediated signaling in a concentration-dependent manner in vivo; Supplementary Figure 2: 7rh inhibits Ddr1 activation in Pan02 tumors; Supplementary Figure 3: Inhibition of Ddr1 with 7rh does not induce observable toxicity; Supplementary Figure 4: 7rh in combination with chemotherapy reduced collagen deposition and AsPC-1 tumor weight; Supplementary Figure 5: 7rh in combination with chemotherapy reduced collagen deposition and KPC tumor weight
Supplementary Figure S2 from Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
Authors: Uitdehaag Joost C.M. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Willemsen-Seegers Nicole , de Vetter Judith R.F. , Dylus Jelle , van Doornmalen Antoon M. , Kooijman Jeffrey , Sawa Masaaki , van Gerwen Suzanne J.C. , de Man Jos , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Additional clustering data
Supplementary Figure S1 from Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
Authors: Uitdehaag Joost C.M. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Willemsen-Seegers Nicole , de Vetter Judith R.F. , Dylus Jelle , van Doornmalen Antoon M. , Kooijman Jeffrey , Sawa Masaaki , van Gerwen Suzanne J.C. , de Man Jos , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Additional reproducibility data
Supplemental Figure Legends from Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer
Authors: Railkar Reema , Krane L. Spencer , Li Q. Quentin , Sanford Thomas , Siddiqui Mohammad Rashid , Haines Diana , Vourganti Srinivas , Brancato Sam J. , Choyke Peter L. , Kobayashi Hisataka , Agarwal Piyush K.
Published: April 2023

Figure legends for all supplemental files
Supplementary file-Synthesis from Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation
Authors: Samadder Pounami , Suchánková Tereza , Hylse Ondřej , Khirsariya Prashant , Nikulenkov Fedor , Drápela Stanislav , Straková Nicol , Vaňhara Petr , Vašíčková Kateřina , Kolářová Hana , Binó Lucia , Bittová Miroslava , Ovesná Petra , Kollár Peter , Fedr Radek , Ešner Milan , Jaroš Josef , Hampl Aleš , Krejčí Lumír , Paruch Kamil , Souček Karel
Published: April 2023

Detail description of synthesis and supporting data
Supplementary table 1 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
Authors: Zeng Shan , Seifert Adrian M. , Zhang Jennifer Q. , Cavnar Michael J. , Kim Teresa S. , Balachandran Vinod P. , Santamaria-Barria Juan A. , Cohen Noah A. , Beckman Michael J. , Medina Benjamin D. , Rossi Ferdinand , Crawley Megan H. , Loo Jennifer K. , Maltbaek Joanna H. , Besmer Peter , Antonescu Cristina R. , DeMatteo Ronald P.
Published: April 2023

Primary untreated KIT+ vs. Metastatic resistant KIT+, pathways with P< 0.05.
Supplementary Table 1 from Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Authors: Gautam Jaya , Ku Jin-Mo , Regmi Sushil Chandra , Jeong Hyunyoung , Wang Ying , Banskota Suhrid , Park Myo-Hyeon , Nam Tae-gyu , Jeong Byeong-Seon , Kim Jung-Ae
Published: April 2023

Primer sequences used in the PCR experiments
Supplementary Figure S1 from Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Authors: Gautam Jaya , Ku Jin-Mo , Regmi Sushil Chandra , Jeong Hyunyoung , Wang Ying , Banskota Suhrid , Park Myo-Hyeon , Nam Tae-gyu , Jeong Byeong-Seon , Kim Jung-Ae
Published: April 2023

Effects of BJ-1301 and Î±-TOH on cell viability, proliferation, and VEGF-induced tube formation. A, Effects of Î±-TOH or BJ-1301 on the viability of HUVECs and BAOECs were determined using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. B, Effect of BJ-1301 alone treatment on HUVEC proliferation. C, HUVECs plated in a well coated with Matrigel basement membrane matrix, were treated with compounds in the presence of VEGF (20 ng/ml). The total tube length per field was measured using Image Inside software (Upper panel). Invasion of HUVECs was measured using VEGF-induced HUVEC migration in the Transwell assay (Lower panel). The bar graphs represent the mean {plus minus} S.E.M. of three independent experiments. *P<0.05 versus vehicle-treated control. #P<0.05 versus VEGF alone. D, Inhibitory effect of BJ-1301 on VEGF-induced tube formation in a time-dependent manner.
Supplementary Figure S2 from Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy
Authors: Järnum Sofia , Runström Anna , Bockermann Robert , Winstedt Lena , Crispin Max , Kjellman Christian
Published: April 2023

IdeS effect on Daudi cell proliferation for 48 hours
Supplemental Figure 1 from Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption
Authors: Xu Leqin , Luo Jian , Jin Rongrong , Yue Zhiying , Sun Peng , Yang Zhengfeng , Yang Xinghai , Wan Wei , Zhang Jishen , Li Shichang , Liu Mingyao , Xiao Jianru
Published: April 2023

Western blotting analysis of phosphorylated p65 (p-p65) in normal bone tissues (n=7) and GCTB tumor tissues (n=7).
Supplemental Figure 2 from Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer
Authors: MacDonald Amanda , Priess Michelle , Curran Jennifer , Guess Jamey , Farutin Victor , Oosterom Ilse , Chu Chia Lin , Cochran Edward , Zhang Lynn , Getchell Kristen , Lolkema Martijn , Schultes Birgit C. , Krause Silva
Published: April 2023

Supplemental Figure 2 shows GM6001 reduced spheroid growth and invasion in the 3D co-culture model.
Supplementary Figure 4 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
Authors: Chen Luxi , Yuan Yi , Kar Shreya , Kanchi Madhu M. , Arora Suruchi , Kim Ji E. , Koh Pei F. , Yousef Einas , Samy Ramar P. , Shanmugam Muthu K. , Tan Tuan Z. , Shin Sung W. , Arfuso Frank , Shen Han M. , Yang Henry , Goh Boon C. , Park Joo I. , Gaboury Louis , Lobie Peter E. , Sethi Gautam , Lim Lina H.K. , Kumar Alan P.
Published: April 2023

Supplementary Figure 4: PPARγ ligand-induced changes in expression of RIP1 and NEMO and therefore NFκB activity are receptor dependent.
Figure S5 from Mutual Influence of ROS, pH, and CLIC1 Membrane Protein in the Regulation of G1–S Phase Progression in Human Glioblastoma Stem Cells
Authors: Peretti Marta , Raciti Federica Maddalena , Carlini Valentina , Verduci Ivan , Sertic Sarah , Barozzi Sara , Garré Massimiliano , Pattarozzi Alessandra , Daga Antonio , Barbieri Federica , Costa Alex , Florio Tullio , Mazzanti Michele
Published: April 2023

Current density/voltage relationships of CLIC1 current in CSCs
Figure S8 from IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma
Authors: Long Kristen B. , Tooker Graham , Tooker Evan , Luque Santiago Lombo , Lee Jae W. , Pan Xiaoqing , Beatty Gregory L.
Published: April 2023

Cleaved caspase 3 (CC3) expression in tumors treated with or without IL-6Ralpha antibodies and gemcitabine chemotherapy
Figure S2 from IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma
Authors: Long Kristen B. , Tooker Graham , Tooker Evan , Luque Santiago Lombo , Lee Jae W. , Pan Xiaoqing , Beatty Gregory L.
Published: April 2023

IL-6Ralpha expression on human PBMCs
Supplementary Materials and Methods from A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
Authors: Machida Yukino , Nakagawa Makoto , Matsunaga Hironori , Yamaguchi Masayuki , Ogawara Yoko , Shima Yutaka , Yamagata Kazutsune , Katsumoto Takuo , Hattori Ayuna , Itoh Masato , Seki Takahiko , Nishiya Yumi , Nakamura Koichi , Suzuki Kanae , Imaoka Tomoki , Baba Daichi , Suzuki Makoto , Sampetrean Oltea , Saya Hideyuki , Ichimura Koichi , Kitabayashi Issay
Published: April 2023

Supplementary Data shows Supplementary Materials and Methods
Figure S3 from A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
Authors: Machida Yukino , Nakagawa Makoto , Matsunaga Hironori , Yamaguchi Masayuki , Ogawara Yoko , Shima Yutaka , Yamagata Kazutsune , Katsumoto Takuo , Hattori Ayuna , Itoh Masato , Seki Takahiko , Nishiya Yumi , Nakamura Koichi , Suzuki Kanae , Imaoka Tomoki , Baba Daichi , Suzuki Makoto , Sampetrean Oltea , Saya Hideyuki , Ichimura Koichi , Kitabayashi Issay
Published: April 2023

The growth of IDH wild-type glioblastoma is not affected by DS-1001b treatment in a subcutaneous PDX model.
Supplementary Figure 4 from Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin
Authors: Nagel Remco , Avelar Ana Teresa , Aben Nanne , Proost Natalie , van de Ven Marieke , van der Vliet Jan , Cozijnsen Miranda , de Vries Hilda , Wessels Lodewyk F. A. , Berns Anton
Published: April 2023

Supplementary figure 4. Cell viability data based to generate the synergy plots in Figures 2 and 3.
Supplementary Figure 3 from Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin
Authors: Nagel Remco , Avelar Ana Teresa , Aben Nanne , Proost Natalie , van de Ven Marieke , van der Vliet Jan , Cozijnsen Miranda , de Vries Hilda , Wessels Lodewyk F. A. , Berns Anton
Published: April 2023

Supplementary figure 3A and B. Graph representing the mRNA levels of MYC and MYCL1 in a panel of 63 human SCLC cell lines. Cut-offs for the analysis of low and high expressing cells were set as indicated. C. Graphs showing the 2log(IC50) for a selection of CHK1 and ATR inhibitors of a panel of 63 human SCLC cell lines screened by Polley at al. (21). Cell lines were grouped on the basis of absence or presence of either MYC or MYCL1 expression. D. p-values for testing between the MYC/MYCL1 low and either high group were calculated using a Mann- Whitney U test and were corrected for multiple testing using Benjamini-Hochberg.
Supplementary Figure 6 from Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
Authors: Pishas Kathleen I. , Drenberg Christina D. , Taslim Cenny , Theisen Emily R. , Johnson Kirsten M. , Saund Ranajeet S. , Pop Ioana L. , Crompton Brian D. , Lawlor Elizabeth R. , Tirode Franck , Mora Jaume , Delattre Olivier , Beckerle Mary C. , Callen David F. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Protein expression of ER-stress response genes following treatment with SP-2509
Supplementary Figure 2 from Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
Authors: Pishas Kathleen I. , Drenberg Christina D. , Taslim Cenny , Theisen Emily R. , Johnson Kirsten M. , Saund Ranajeet S. , Pop Ioana L. , Crompton Brian D. , Lawlor Elizabeth R. , Tirode Franck , Mora Jaume , Delattre Olivier , Beckerle Mary C. , Callen David F. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Targeted KDM1A inhibition and EWS/FLI knockdown induces similar transcriptional signatures
Supplementary Figure 3 from Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy
Authors: Creevey Laura , Bleach Rachel , Madden Stephen F. , Toomey Sinead , Bane Fiona T. , Varešlija Damir , Hill Arnold D. , Young Leonie S. , McIlroy Marie
Published: April 2023

Gene changes in MCF7aro. The impact of cyp19 overexpression on SGK3 expression in an independent study. Impact of siRNA-AR/ER on SGK3 mRNA
Supplementary Figure 3 from A Tricin Derivative from Deschampsia antarctica Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response
Authors: Malvicini Mariana , Gutierrez-Moraga Ana , Rodriguez Marcelo M. , Gomez-Bustillo Sofia , Salazar Lorena , Sunkel Carlos , Nozal Leonor , Salgado Antonio , Hidalgo Manuel , Lopez-Casas Pedro P. , Novella Jose Luis , Vaquero Juan Jose , Alvarez-Builla Julio , Mora Adda , Gidekel Manuel , Mazzolini Guillermo
Published: April 2023

Toxicology analysis. Liver transaminases aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured after Antartina{trade mark, serif} treatment and H&E stained tissues from BALB/c mice untreated (n= 5) or treated with 5 mg/kg (n=5) and 50 mg/kg (n=5) of Antartina{trade mark, serif}
Supplementary Table S3 from The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics
Authors: Martens-de Kemp Sanne R. , Brink Arjen , van der Meulen Ida H. , de Menezes Renée X. , te Beest Dennis E. , Leemans C. René , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table S3. Number of siRNAs that were confirmed to cause the cisplatin sensitizing phenotype after deconvolution of the siRNA pool.
Figure S5 from Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells
Authors: Wang Rui , Li Ying , Gong Ping , Gabrilove Janice , Waxman Samuel , Jing Yongkui
Published: April 2023

The effect of Sorafenib and ATO combination on the body weight of mice.
Supporting Video 07 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Molecular dynamics simulations of the wild type Eg5-Arry-520 complex.
Supporting Video 04 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Time lapse imaging of U2OS-Eg5(L214A) expressing cells exposed to 10 nM Arry-520 and followed for 16h. Cells divide uninhibited.
Supplementary Figure Legends from Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer
Authors: Li Jie , Wang Ruixin , Kong Yifan , Broman Meaghan M. , Carlock Colin , Chen Long , Li Zhiguo , Farah Elia , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

Figure legends of the supplementary figures
Supplementary Materials from A Spatio-Temporal Model of Macrophage-Mediated Drug Resistance in Glioma Immunotherapy
Authors: Zheng Yongjiang , Bao Jiguang , Zhao Qiyi , Zhou Tianshou , Sun Xiaoqiang
Published: April 2023

This Supplementary file includs Text S1-S6, Figure S1-S6 and Table S1-S2. Text S1:Dimensionless equations. Text S2: Radial symmetry simplification of the system. Text S3: Initial and boundary conditions. Text S4: Parameter estimation. Text S5: Two-parameter sensitivity analysis. Text S6: Stochastic simulation and the computation of survival times. Figure S1: Simulated spatio-temporal profiles of cancer cells and microenvironment using the model with increased drug consumption rate (10 ). Figure S2: Model behavior under different values of some critical parameters including r1, d1, B2 and Dd. Figure S3: Sensitivity analysis for parameter combination. Figure S4: Dose-dependent sensitivities of the killing rate and the regrowth rate of cancer cells under treatment with different doses of a CSF1R inhibitor. Figure S5: The dynamics of drug response simulated from the model with initial condition (a) of macrophages as in Text S3. Figure S6: The dynamics of drug response simulated from the model with initial condition (b) of macrophages as in Text S3. Table S1: Values of dimensional parameters. Table S2: Values of dimensionless parameters.
Supplementary Movie S3 from Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C–Derived Peptide TNIIIA2
Authors: Fujita Motomichi , Yamamoto Tetsuya , Iyoda Takuya , Fujisawa Tatsuya , Sasada Manabu , Nagai Reo , Kudo Chikako , Otsuka Kazuki , Kamiya Sadahiro , Kodama Hiroaki , Fukai Fumio
Published: April 2023

Time lapse evaluation of cell scattering (TNIIIA2 + FNIII14)
Supplementary Materials and Methods from Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C–Derived Peptide TNIIIA2
Authors: Fujita Motomichi , Yamamoto Tetsuya , Iyoda Takuya , Fujisawa Tatsuya , Sasada Manabu , Nagai Reo , Kudo Chikako , Otsuka Kazuki , Kamiya Sadahiro , Kodama Hiroaki , Fukai Fumio
Published: April 2023

This file shows the materials and methods in the results of 'Supplementary Figure'.
Figure Legends from Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications
Authors: Saidu Nathaniel Edward Bennett , Noé Gaëlle , Cerles Olivier , Cabel Luc , Kavian-Tessler Niloufar , Chouzenoux Sandrine , Bahuaud Mathilde , Chéreau Christiane , Nicco Carole , Leroy Karen , Borghese Bruno , Goldwasser François , Batteux Frédéric , Alexandre Jérôme
Published: April 2023

Supplementary Figure Legends
Supplemental Methods, supplemental tables 1 to 7, and supplemental figures 1 to 9 from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
Authors: Inda Márcia A. , Blok Erik J. , Kuppen Peter J.K. , Charehbili Ayoub , den Biezen-Timmermans Eveline C. , van Brussel Anne , Fruytier Sevgi E. , Meershoek-Klein Kranenbarg Elma , Kloet Susan , van der Burg Bart , Martens John W.M. , Sims Andrew H. , Turnbull Arran K. , Dixon J. Michael , Verhaegh Wim , Kroep Judith R. , van de Velde Cornelis J.H. , van de Stolpe Anja
Published: April 2023

Supplemental methods on estradiol measurements and sample analysis. Supplemental tables: 1. Public datasets used; 2. Estrogen concentrations on breast tissue; 3. Association of baseline parameters and ERPAS (Edinburgh cohort); 4. Logistic regression analysis (Edinburgh cohort); 5. ERPAS association to response (TEAM IIa cohort); 6. Association of baseline parameters and ERPAS (TEAM IIa cohort); 7. Single nucleotide variants found in TEAM IIa resection samples. Supplemental Figures: 1. Consort diagram of tissue samples (TEAM IIa trial); 2. Agreement between AffyP2 models; 3. Improved performance of AffyP2 1 nM E2 model; 4. Agreement between AffyP2 and AffyA models; 5. Agreement between AffyP2 and TEAMII PCR models; 6. Correlation between baseline and decrease in ERPAS; 7. Non-synonymous ESR1 and PIK3CA mutations in TEAM IIa vs ERPAS; 8. ESR1 coverage on analyzed samples (TEAM IIa cohort); 9. Intra tumor variability of ERPAS resection samples of the TEAM IIa cohort.
Supplementary Figure S7 from Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer
Authors: Duplaquet Leslie , Figeac Martin , Leprêtre Frédéric , Frandemiche Charline , Villenet Céline , Sebda Shéhérazade , Sarafan-Vasseur Nasrin , Bénozène Mélanie , Vinchent Audrey , Goormachtigh Gautier , Wicquart Laurence , Rousseau Nathalie , Beaussire Ludivine , Truant Stéphanie , Michel Pierre , Sabourin Jean-Christophe , Galateau-Sallé Françoise , Copin Marie-Christine , Zalcman Gérard , De Launoit Yvan , Fafeur Véronique , Tulasne David
Published: April 2023

Supplementary Figure S7: Fibroblast transformation with each of the 8 somatic-mutation-harboring RTKs
Figure S3 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Authors: Panowski Siler H. , Kuo Tracy C. , Zhang Yi , Chen Amy , Geng Tao , Aschenbrenner Laura , Kamperschroer Cris , Pascua Edward , Chen Wei , Delaria Kathy , Farias Santiago , Bateman Marjorie , Dushin Russell G. , Chin Sherman M. , Van Blarcom Thomas J. , Yeung Yik Andy , Lindquist Kevin C. , Chunyk Allison G. , Kuang Bing , Han Bora , Mirsky Michael , Pardo Ingrid , Buetow Bernard , Martin Thomas G. , Wolf Jeffrey L. , Shelton David , Rajpal Arvind , Strop Pavel , Chaparro-Riggers Javier , Sasu Barbra J.
Published: April 2023

BCMA bispecific is highly active in vivo.
Table S3: Primers for qRT-PCR from TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing
Authors: Liu Tieju , Sun Huizhi , Zhu Dongwang , Dong Xueyi , Liu Fang , Liang Xiaohui , Chen Chen , Shao Bing , Wang Meili , Wang Yi , Sun Baocun
Published: April 2023

Table S3: Primers for qRT-PCR
Supplementary Figure S1 from TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing
Authors: Liu Tieju , Sun Huizhi , Zhu Dongwang , Dong Xueyi , Liu Fang , Liang Xiaohui , Chen Chen , Shao Bing , Wang Meili , Wang Yi , Sun Baocun
Published: April 2023

The gene structure view of CALU (exon2 inclusion), RSRC2 (exon4 inclusion), CEACAM1 (exon7 inclusion), LMCD1 (exon3 exclusion), PALM (exon8 exclusion) and RFWD2 (exon7 exclusion).
Figure S3 from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
Authors: Liu Shuying , Li Shunqiang , Wang Bailiang , Liu Wenbin , Gagea Mihai , Chen Huiqin , Sohn Joohyuk , Parinyanitikul Napa , Primeau Tina , Do Kim-Anh , Vande Woude George F. , Mendelsohn John , Ueno Naoto T. , Mills Gordon B. , Tripathy Debu , Gonzalez-Angulo Ana M.
Published: April 2023

Establish MCF-10A derived cells expression of PIK3CA/MET genes
Figure S1 from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
Authors: Liu Shuying , Li Shunqiang , Wang Bailiang , Liu Wenbin , Gagea Mihai , Chen Huiqin , Sohn Joohyuk , Parinyanitikul Napa , Primeau Tina , Do Kim-Anh , Vande Woude George F. , Mendelsohn John , Ueno Naoto T. , Mills Gordon B. , Tripathy Debu , Gonzalez-Angulo Ana M.
Published: April 2023

MET gene constructs
Figure S1 from The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway
Authors: Cho Hee-Yeon , Thein Thu Zan , Wang Weijun , Swenson Stephen D. , Fayngor Rochelle A. , Ou Mengting , Marín-Ramos Nagore I. , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

NEO214 concentrations in the mouse brain and in serum.
Supplementary Figure S2 from Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model
Authors: Stallons Tania A. Rozgaja , Saidi Amal , Tworowska Izabela , Delpassand Ebrahim S. , Torgue Julien J.
Published: April 2023

A biodistribution study was done in CD-1 non-tumor bearing mice to compare the male and female organ uptake of 212Pb-DOTAMTATE at 4hr and 24hr post drug injection. No significant difference is observed between the two sexes in all critical organs at either of the two timepoints. The overall slightly higher tissue uptake observed in females as compared to the males is due to female organs being generally smaller. The uptake in %ID is similar among the two sexes (Panel A). A biodistribution study in athymic nude tumor bearing mice showed that specific activity had no significant effect on tumor uptake at 24hours post drug injection in tumors that received 4.1ng/10µCi injection up to 110ng/10µCi injection (Panel B).
Supplementary Figure S6 from Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma
Authors: Xu Kexin , Sun Geng , Li Min , Chen Hongling , Zhang Zuhao , Qian Xixi , Li Ping , Xu Lin , Huang Wenbin , Wang Xuerong
Published: April 2023

Supplementary Figure S6 shows knockdown of KLF4 expression promoted cell growth, EMT, and migration.
Supplemental Table 2 from Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
Authors: Gowda Raghavendra , Kardos Gregory , Sharma Arati , Singh Sanjay , Robertson Gavin P.
Published: April 2023

Supplemental Table 2. CelePlum-777 caused negligible systemic toxicity.
Supplemental Table 1 from Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
Authors: Gowda Raghavendra , Kardos Gregory , Sharma Arati , Singh Sanjay , Robertson Gavin P.
Published: April 2023

Supplemental Table 1. Biochemical and stability characterization of CelePlum-777 containing varying drug ratios
Supplemental Figure 4 from Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
Authors: Gowda Raghavendra , Kardos Gregory , Sharma Arati , Singh Sanjay , Robertson Gavin P.
Published: April 2023

Supplemental Figure 4. CelePlum-777 led to synergistic killing of melanoma cell lines lacking (V600E)-BRAF
Supplemental Figure 1 from Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
Authors: Gowda Raghavendra , Kardos Gregory , Sharma Arati , Singh Sanjay , Robertson Gavin P.
Published: April 2023

Supplemental Figure 1. Selection of Plumbagin dose for optimal drug synergy
Supplementary Table S5 from A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells
Authors: Maekawa Hisatsugu , Miyoshi Hiroyuki , Yamaura Tadayoshi , Itatani Yoshiro , Kawada Kenji , Sakai Yoshiharu , Taketo M. Mark
Published: April 2023

Patient outcome and drug sensitivity with PDSXs
Supplementary Table S4 from A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells
Authors: Maekawa Hisatsugu , Miyoshi Hiroyuki , Yamaura Tadayoshi , Itatani Yoshiro , Kawada Kenji , Sakai Yoshiharu , Taketo M. Mark
Published: April 2023

Relative tumor volumes and their variances in drug-dosing tests for PDSX and PDX (Day 22)
Supplementary Table S2 & S3 from A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells
Authors: Maekawa Hisatsugu , Miyoshi Hiroyuki , Yamaura Tadayoshi , Itatani Yoshiro , Kawada Kenji , Sakai Yoshiharu , Taketo M. Mark
Published: April 2023

Supplementary Table S2 Details of 21 cases of PDSXs & Supplementary Table S3. Correlations of drug-dosing results between PDSX and PDX methods
Supplementary Figure 5 from Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
Authors: Hingorani Dina V. , Doan Matthew K. , Camargo Maria F. , Aguilera Joseph , Song Seung M. , Pizzo Donald , Scanderbeg Daniel J. , Cohen Ezra E.W. , Lowy Andrew M. , Adams Stephen R. , Advani Sunil J.
Published: April 2023

MMAF anti-HER2 antibody conjugates increase tumor G2/M fraction.
Supplementary methods from TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
Authors: Ito Kimihiro , Nishio Makoto , Kato Masanori , Murakami Haruyasu , Aoyagi Yoshimi , Ohe Yuichiro , Okayama Takashige , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Gotaro , Nonoshita Katsumasa , Ito Satoru , Matsuo Kenichi , Miyadera Kazutaka
Published: April 2023

Supplementary methods shows "Synthesis of TAS-121" and the metohds that is relevant to the experiments shown in Supplementary datas.
Supplementary Table S2 from TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
Authors: Ito Kimihiro , Nishio Makoto , Kato Masanori , Murakami Haruyasu , Aoyagi Yoshimi , Ohe Yuichiro , Okayama Takashige , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Gotaro , Nonoshita Katsumasa , Ito Satoru , Matsuo Kenichi , Miyadera Kazutaka
Published: April 2023

Supplementary Table S2 shows the case reports of clinical activity and AUC0-24h of TAS-121.
Supplementary FigS1 from TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
Authors: Ito Kimihiro , Nishio Makoto , Kato Masanori , Murakami Haruyasu , Aoyagi Yoshimi , Ohe Yuichiro , Okayama Takashige , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Gotaro , Nonoshita Katsumasa , Ito Satoru , Matsuo Kenichi , Miyadera Kazutaka
Published: April 2023

Supplementary Fig. S1 shows chemical structure and binding mode of TAS-121.
Figure S6 from RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer
Authors: Goka Erik T. , Chaturvedi Pallavi , Lopez Dayrelis T. Mesa , Garza Adriana De La , Lippman Marc E.
Published: April 2023

Figure S6. (A) Five different colorectal cancer cells showing the sensitivity for GYS32661, KRAS and BRAF mutation and Rac1b expression. (B) HCT116-EV and HCT116-Rac1b cells stably expressing the NFÎºÎ' reporter was treated with different dose of GYS32661. The cells were lysed in reporter lysis buffer and NFÎºB reporter activity was measured. The results, presented as the NF-kB-mediated luciferase activity normalized to the protein concentration are the means {plus minus} SEM from three independent experiments. (C) Mice body weight following treatment with GYS32661.
Supplementary Figures S1, S2, S3 from Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Authors: Roy Riti , Winteringham Louise N. , Lassmann Timo , Forrest Alistair R.R.
Published: April 2023

Supplementary Figure 1: Comparison of correlations for ALK and MET. Blue, red and grey cells denote significant correlations, significant anti-correlations and non-significant correlations respectively. White cells correspond to combinations that were not tested or are not valid drug-target pairs. Supplementary Figure 2: Comparison of correlations for HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8. Blue, red and grey cells denote significant correlations, significant anti-correlations and non-significant correlations respectively. White cells correspond to combinations that were not tested or are not valid drug-target pairs. Supplementary Figure 3: Summary of the degree of overlap between the GDSC and CTRP analyses at the transcript level. As GDSC and CTRP provide gene-level expression measurements from different microarray versions (Affymetrix GeneChip HG-U133A in GDSC and HG-U133PLUS2 in CTRP) which potentially detect different isoforms of each gene, we repeated our concordance analysis at the transcript level. The correlation coefficient was calculated for 74 common drugs (targeting drug-target transcript isoforms). The 541 cell lines common in GDSC and CTRP where drug-target transcript isoform expression and AUC values could be obtained were considered.
Figure S5 from SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status
Authors: Fujihara Kenji M. , Corrales Benitez Mariana , Cabalag Carlos S. , Zhang Bonnie Z. , Ko Hyun S. , Liu David S. , Simpson Kaylene J. , Haupt Ygal , Lipton Lara , Haupt Sue , Phillips Wayne A. , Clemons Nicholas J.
Published: April 2023

Figure S5 shows MYC directly regulates SLC7A11 levels and APR-246 sensitivity.
Supplementary Figure 1 from Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses
Authors: Martomo Stella A. , Lu Dan , Polonskaya Zhanna , Luna Xenia , Zhang Zhikai , Feldstein Sam , Lumban-Tobing Radovan , Almstead Danielle K. , Miyara Faical , Patel Jeegar
Published: April 2023

Generation and characterization of KD033/srKD033/ntKD033